IAS
NTLA icon

Insigneo Advisory Services’s Intellia Therapeutics NTLA Stock Holding History

Insigneo Advisory Services’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$203K Buy
12,000
+1,970
+20% +$27.6K 0.01% 782
2026
Q1 		$129K Hold
10,030
– – 0.01% 670
2025
Q4 		$90.2K Buy
+10,030
New +$138K 0.01% 680

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Insigneo Advisory Services's NTLA Position: Q2 2026 in Review

Insigneo Advisory Services increased its Intellia Therapeutics (NTLA) stake by 20% in Q2 2026, buying an estimated $27.6K and bringing the position to 12,000 shares worth $203K. The position accounts for 0.01% of the portfolio, ranked #782.

Insigneo Advisory Services first reported a position in NTLA in Q4 2025 and has held it in 3 quarters since. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Insigneo Advisory Services held 12,000 shares of Intellia Therapeutics worth $203K as of Q2 2026.
  • Insigneo Advisory Services bought 1,970 Intellia Therapeutics shares in Q2 2026, an estimated $27.6K.
  • Intellia Therapeutics made up 0.01% of Insigneo Advisory Services's portfolio in Q2 2026, its #782 holding.
  • Insigneo Advisory Services first reported a position in Intellia Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Insigneo Advisory Services's 13F filing for Q2 2026, filed 14 Aug 2026.